



Attorney Docket No.: 121753-1004

RECEIVED  
OCT 28 2003  
PATENT  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re the Application of: Lorraine F. Meisner  
Serial No.: 09/997,663  
Group Art Unit: 1616  
Filed: November 29, 2001  
Examiner: Frank I. Choi  
For: COMPOSITIONS AND METHODS FOR THE TREATMENT  
SKIN

Commissioner for Patents  
Washington, D.C. 20231

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

As listed on the accompanying form PTO-1449, submitted herewith are copies of the indicated references which Applicant believes may be material to the examination of the above-identified application, and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

The filing of this supplemental information disclosure statement shall not be construed as a representation that a search has been made, an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. Further, the filing of this supplemental information disclosure statement shall not be construed as an admission against interest in any manner. Written notification that the enclosed references have been considered in their entirety by return of a copy of the enclosed form, completed by the Examiner, is respectfully requested.

**IDENTIFICATION OF TIME OF FILING THE  
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

- ☐ This Supplemental Information Disclosure Statement is being filed within three months of the filing date of the national application.
- ☐ This Supplemental Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in §1.491 in an international

#1175735 V1 - 121753-1004 SUPPLEMENTAL IDS FILED AUG02

Express Mail Label No.  
EL 859 423 451 US

- ☐ This Supplemental Information Disclosure Statement is being filed before the mailing date of the First Office Action on the merits.
- ☒ This Supplemental Information Disclosure Statement is being filed after three months of the filing date of the national application or after three months of the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office Action on the merits, but before the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application.

Accompanying this transmittal is:

- ☐ a statement specified in 37 CFR § 1.97(e); or
- ☐ a fee set forth in 37 CFR § 1.17(p)
- ☐ This Supplemental Information Disclosure Statement is being filed after the mailing date of a final action under § 1.113, or a notice of allowance under § 1.311 but before the payment of the issue fee.

Accompanying this transmittal is:

1. a statement as specified in 37 CFR § 1.97(e); and
2. a fee set forth in 37 CFR § 1.17(p)

STATEMENT FOR SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT 37 CFR 1.97(e)  
(Only if Required Above)

I, the person(s) signing below hereby states that:

- ☒ each item of information contained in the supplemental information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the supplemental information disclosure statement. 37 CFR § 1.97(e)(1); or
- ☐ no item of information contained in the supplemental information disclosure statement was cited in a communication from a foreign patent office in the counterpart foreign application to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contained in the supplemental information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the supplemental information disclosure statement. 37 CFR § 1.97(e)(2).

designated in § 1.56(c) more than three months prior to the filing of the supplemental information disclosure statement. 37 CFR § 1.97(e)(2).

#### FEE PAYMENT

- ☐ attached is a check in the amount of \$ \_\_\_\_\_
- ☐ charge Deposit Account No. 07-0153  
in the amount of \$ \_\_\_\_\_

Applicants believe no additional fees are due for the filing of this Supplemental Information Disclosure Statement. However, if any additional fees are due, or any overpayments have been made, please charge, or credit, Deposit Account No. 07-0153.

Date: August 14, 2002

Respectfully submitted,

GARDERE WYNNE SEWELL L.L.P.



Edwin S. Flores

Reg. No.: 38,453

ATTORNEY FOR APPLICANTS

1601 Elm Street, Suite 3000  
Dallas, Texas 75201  
(214) 999-4559 - Telephone  
(214) 999-3559 - Facsimile

FORM PTO-1449  
(REV. 7.80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
121753-1004SERIAL NO.:  
09/997,663LIST OF PRIOR ART CITED BY APPLICANT  
(Use several sheets if necessary)APPLICANT:  
Lorraine F. MeisnerFILING DATE:  
November 29, 2001GROUP:  
1616

## U. S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	5,554,647	09/10/1996	Perricone	514	474	04/27/1995

## OTHER PRIOR ART

R. Austria, A. Semenzato, A. Bettero, "Stability of vitamin C derivatives in solution and topical formulations," 1997, J Pharm. Biomed. Anal. 15:795-801.

K. Ash, et al., "Comparison of Topical Therapy for Stiae Alba (20% Glycolic Acid/0.05% Tretinoin Versus 20% Glycolic Acid/10% L-Ascorbic Acid), 1998, Dermatol Sur g 24:849-856.

Paul A. Seib and Bert M. Tolbert, "Ascorbic Acid: Chemistry, Metabolism and Uses," American Chemical Society, 1992, pp. 419-423.

Edward Staunton West, Ph.D., Wilbert R. Todd, Ph.D., Howard S. Mason, Ph.D. and John T. Van Bruggen, Ph.D., "Textbook of Biochemi," Fourth Edition, 1966, pp. 823-795.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.